Roy Blum

Lee Lab


Bioinformatics Specialist


Email

Publications
    2017
  1. Wang CY, Froberg JE, Blum R, Jeon Y, Lee JT. Comment on "Xist recruits the X chromosome to the nuclear lamina to enable chromosome-wide silencing". Science 2017 Jun 16; 356(6343)

  2. 2015
  3. Blum R. Stepping inside the realm of epigenetic modifiers. Biomol Concepts 2015 Apr 1; 6(2):119-36.

  4. 2014
  5. Blum R. Activation of muscle enhancers by MyoD and epigenetic modifiers. J. Cell. Biochem. 2014 Nov; 115(11):1855-67.

  6. Vitanza NA, Zaky W, Blum R, Meyer JA, Wang J, Bhatla T, Morrison DJ, Raetz EA, Carroll WL. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. Pediatr Blood Cancer 2014 Oct; 61(10):1779-85.

  7. Jones CL, Bhatla T, Blum R, Wang J, Paugh SW, Wen X, Bourgeois W, Bitterman DS, Raetz EA, Morrison DJ, Teachey DT, Evans WE, Garabedian MJ, Carroll WL. Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model. J. Biol. Chem. 2014 Jul 25; 289(30):20502-15.

  8. Cheng J, Blum R, Bowman C, Hu D, Shilatifard A, Shen S, Dynlacht BD. A role for H3K4 monomethylation in gene repression and partitioning of chromatin readers. Mol. Cell 2014 Mar 20; 53(6):979-92.

  9. Blum R, Kloog Y. Metabolism addiction in pancreatic cancer. Cell Death Dis 2014; 5:e1065.

  10. 2013
  11. Blum R, Dynlacht BD. The role of MyoD1 and histone modifications in the activation of muscle enhancers. Epigenetics 2013 Aug; 8(8):778-84.

  12. 2012
  13. Blum R, Vethantham V, Bowman C, Rudnicki M, Dynlacht BD. Genome-wide identification of enhancers in skeletal muscle: the role of MyoD1. Genes Dev. 2012 Dec 15; 26(24):2763-79.

  14. Vazquez-Cintron EJ, Monu NR, Burns JC, Blum R, Chen G, Lopez P, Ma J, Radoja S, Frey AB. Protocadherin-18 is a novel differentiation marker and an inhibitory signaling receptor for CD8+ effector memory T cells. PLoS ONE 2012; 7(5):e36101.

  15. 2011
  16. Asp P, Blum R, Vethantham V, Parisi F, Micsinai M, Cheng J, Bowman C, Kluger Y, Dynlacht BD. Genome-wide remodeling of the epigenetic landscape during myogenic differentiation. Proc. Natl. Acad. Sci. U.S.A. 2011 May 31; 108(22):E149-58.

  17. 2010
  18. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G, Wang X, Zavadil J, Moscatelli D, Wilson EL. Molecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal-epithelial signaling pathways. PLoS ONE 2010; 5(9)

  19. 2009
  20. Blum R, Gupta R, Burger PE, Ontiveros CS, Salm SN, Xiong X, Kamb A, Wesche H, Marshall L, Cutler G, Wang X, Zavadil J, Moscatelli D, Wilson EL. Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS ONE 2009; 4(5):e5722.

  21. 2008
  22. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov 2008 Jan; 3(1):31-47.

  23. 2007
  24. Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G, Shamir R, Kloog Y. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res. 2007 Apr 1; 67(7):3320-8.

  25. 2006
  26. Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol. Cancer Ther. 2006 Sep; 5(9):2337-47.

  27. Erlich S, Tal-Or P, Liebling R, Blum R, Karunagaran D, Kloog Y, Pinkas-Kramarski R. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem. Pharmacol. 2006 Aug 14; 72(4):427-36.

  28. Blum R, Nakdimon I, Goldberg L, Elkon R, Shamir R, Rechavi G, Kloog Y. E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition. Int. J. Cancer 2006 Aug 1; 119(3):527-38.

  29. 2005
  30. Blum R, Kloog Y. Tailoring Ras-pathway--inhibitor combinations for cancer therapy. Drug Resist. Updat. 2005 Dec; 8(6):369-80.

  31. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res. 2005 Feb 1; 65(3):999-1006.

Back to top